Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
17
SAVA Quote, Financials, Valuation and Earnings
Last price:
$2.03
Seasonality move
:
2.5%
Day range:
$1.92 - $2.07
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.20x
Volume:
584.8K
Avg. volume:
771.3K
1-year change:
-13.25%
Market cap:
$98.1M
Revenue:
--
EPS (TTM):
-$2.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$848.7M | $1.31 | 11.96% | 37.26% | $89.09 |
|
FOLD
Amicus Therapeutics, Inc.
|
$182.1M | $0.15 | 29.62% | 267.32% | $14.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OVID
Ovid Therapeutics, Inc.
|
$33.3K | -$0.08 | -17.63% | -24.79% | $4.05 |
|
YCBD
cbdMD, Inc.
|
$4.8M | -- | -5% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
$2.03 | $8.00 | $98.1M | -- | $0.00 | 0% | 2.69x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$58.13 | $89.09 | $11.2B | 21.78x | $0.00 | 0% | 3.68x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.30 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.32x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$0.76 | $0.85 | $95.9M | 1.28x | $0.80 | 0% | 1.48x |
|
OVID
Ovid Therapeutics, Inc.
|
$1.60 | $4.05 | $113.9M | -- | $0.00 | 0% | 17.20x |
|
YCBD
cbdMD, Inc.
|
$0.92 | $2.00 | $8.2M | -- | $0.00 | 0% | 0.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.633 | -- | 2.21x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -2.840 | 8.08% | 1.85x |
|
OVID
Ovid Therapeutics, Inc.
|
23.54% | 4.368 | 14.88% | 3.77x |
|
YCBD
cbdMD, Inc.
|
9.72% | 1.102 | 7.22% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OVID
Ovid Therapeutics, Inc.
|
$115K | -$12.5M | -48.14% | -59.7% | -9487.12% | -$12.9M |
|
YCBD
cbdMD, Inc.
|
$2.5M | -$685.8K | -43.37% | -57.5% | -14.53% | -$243.5K |
Cassava Sciences, Inc. vs. Competitors
-
Which has Higher Returns SAVA or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -3.91%. Cassava Sciences, Inc.'s return on equity of -86.98% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About SAVA or BMRN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 294.09%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.09 which suggests that it could grow by 56.1%. Given that Cassava Sciences, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Cassava Sciences, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is SAVA or BMRN More Risky?
Cassava Sciences, Inc. has a beta of -0.628, which suggesting that the stock is 162.76% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock SAVA or BMRN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or BMRN?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Cassava Sciences, Inc.'s net income of -$10.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 3.68x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M BMRNBioMarin Pharmaceutical, Inc.3.68x 21.78x $786.8M -$30.7M
-
Which has Higher Returns SAVA or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of 10.24%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About SAVA or FOLD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 294.09%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.4%. Given that Cassava Sciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is SAVA or FOLD More Risky?
Cassava Sciences, Inc. has a beta of -0.628, which suggesting that the stock is 162.76% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock SAVA or FOLD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or FOLD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M
-
Which has Higher Returns SAVA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -255.85%. Cassava Sciences, Inc.'s return on equity of -86.98% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SAVA or NBY?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 294.09%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could grow by 11.83%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SAVA or NBY More Risky?
Cassava Sciences, Inc. has a beta of -0.628, which suggesting that the stock is 162.76% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.135, suggesting its less volatile than the S&P 500 by 86.499%.
-
Which is a Better Dividend Stock SAVA or NBY?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or NBY?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cassava Sciences, Inc.'s net income of -$10.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 1.48x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M NBYNovaBay Pharmaceuticals, Inc.1.48x 1.28x $521K -$1.3M
-
Which has Higher Returns SAVA or OVID?
Ovid Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -9210.61%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M OVIDOvid Therapeutics, Inc.87.12% -$0.17 $58.5M -
What do Analysts Say About SAVA or OVID?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 294.09%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 153.06%. Given that Cassava Sciences, Inc. has higher upside potential than Ovid Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Ovid Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 OVIDOvid Therapeutics, Inc.11 0 0 -
Is SAVA or OVID More Risky?
Cassava Sciences, Inc. has a beta of -0.628, which suggesting that the stock is 162.76% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.621%.
-
Which is a Better Dividend Stock SAVA or OVID?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or OVID?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Cassava Sciences, Inc.'s net income of -$10.8M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 17.20x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M OVIDOvid Therapeutics, Inc.17.20x -- $132K -$12.2M
-
Which has Higher Returns SAVA or YCBD?
cbdMD, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -14.4%. Cassava Sciences, Inc.'s return on equity of -86.98% beat cbdMD, Inc.'s return on equity of -57.5%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M YCBDcbdMD, Inc.53.28% -$0.08 $8M -
What do Analysts Say About SAVA or YCBD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 294.09%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 116.71%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 YCBDcbdMD, Inc.0 0 0 -
Is SAVA or YCBD More Risky?
Cassava Sciences, Inc. has a beta of -0.628, which suggesting that the stock is 162.76% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.140, suggesting its more volatile than the S&P 500 by 114.035%.
-
Which is a Better Dividend Stock SAVA or YCBD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or YCBD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than cbdMD, Inc. quarterly revenues of $4.7M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than cbdMD, Inc.'s net income of -$680K. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 0.24x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M YCBDcbdMD, Inc.0.24x -- $4.7M -$680K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
